Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:13 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 20, 2026 | Mar 20, 2025 | Mar 27, 2024 | Mar 23, 2023 | Mar 24, 2022 |
| Operating expenses | $140.9M | $179.6M | $141.5M | $247.4M | $124.9M |
| Research and development | $92.9M | $115.4M | $103.8M | $112.5M | $73.9M |
| Selling, general and administrative | $38.6M | $41.7M | $37.7M | $33.0M | $22.6M |
| Operating income | -$140.9M | -$179.6M | -$141.5M | -$247.4M | -$124.9M |
| Income tax | $0 | – | – | – | – |
| Net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M | -$122.8M |
| EPS, basic | $-0.44 | $-0.69 | $-0.83 | $-1.99 | – |
| EPS, diluted | $-0.44 | $-0.69 | $-0.83 | $-1.99 | – |
| Weighted shares, basic | 283.5M | 233.8M | 150.2M | 122.0M | – |
| Weighted shares, diluted | 283.5M | 233.8M | 150.2M | 122.0M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 20, 2026 | Mar 20, 2025 | Mar 27, 2024 | Mar 23, 2023 | Mar 24, 2022 |
| Cash and equivalents | $73.8M | $67.7M | $93.1M | $284.2M | $360.5M |
| Short-term investments | $202.3M | $230.6M | $219.3M | $151.4M | $54.0M |
| Total current assets | $286.2M | $308.8M | $320.7M | $444.5M | $420.0M |
| Property, plant and equipment | $13.3M | $16.3M | $22.3M | $24.8M | $16.0M |
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M |
| Accounts payable | $981.0K | $468.0K | $2.00M | $23.0M | $4.68M |
| Total current liabilities | $28.5M | $31.4M | $26.2M | $48.7M | $26.4M |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M |
| Shareholders' equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 20, 2026 | Mar 20, 2025 | Mar 27, 2024 | Mar 23, 2023 | Mar 24, 2022 |
| Operating cash flow | -$95.5M | -$109.4M | -$101.2M | -$103.3M | -$79.6M |
| Capital expenditures | $128.0K | $60.0K | $1.77M | $14.6M | $11.2M |
| Free cash flow | -$95.6M | -$109.5M | -$103.0M | -$117.8M | -$90.8M |
| Depreciation and amortization | $3.11M | $3.81M | $3.73M | $2.64M | $829.0K |
| Stock-based compensation | $24.9M | $27.0M | $26.2M | $20.1M | $8.33M |
| Investing cash flow | $100.4M | -$156.6M | -$91.2M | -$71.1M | -$64.6M |
| Financing cash flow | $1.10M | $240.7M | $1.29M | $98.1M | $439.4M |
| Net change in cash | $6.07M | -$25.3M | -$191.1M | -$76.3M | $295.2M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 4, 2026 | 349.8M | +23.3% | SEC |
| May 5, 2026 | 311.0M | +9.8% | SEC |
| Mar 5, 2026 | 310.8M | +9.7% | SEC |
| Nov 5, 2025 | 283.7M | +0.3% | SEC |
| Aug 5, 2025 | 283.7M | +0.4% | SEC |
| May 6, 2025 | 283.3M | +63.4% | SEC |
| Mar 13, 2025 | 283.3M | +87.0% | SEC |
| Nov 5, 2024 | 282.7M | +87.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.